PL2240179T3 - Imidazopirydazyny jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako leku - Google Patents

Imidazopirydazyny jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako leku

Info

Publication number
PL2240179T3
PL2240179T3 PL09707983T PL09707983T PL2240179T3 PL 2240179 T3 PL2240179 T3 PL 2240179T3 PL 09707983 T PL09707983 T PL 09707983T PL 09707983 T PL09707983 T PL 09707983T PL 2240179 T3 PL2240179 T3 PL 2240179T3
Authority
PL
Poland
Prior art keywords
imidazopyridazine
medicine
manufacture
application
par1 inhibitors
Prior art date
Application number
PL09707983T
Other languages
English (en)
Inventor
Uwe Heinelt
Volkmar Wehner
Matthias Herrmann
Karl Schoenafinger
Henning Steinhagen
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of PL2240179T3 publication Critical patent/PL2240179T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL09707983T 2008-02-05 2009-01-23 Imidazopirydazyny jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako leku PL2240179T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290113 2008-02-05
EP09707983.4A EP2240179B1 (de) 2008-02-05 2009-01-23 Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
PL2240179T3 true PL2240179T3 (pl) 2017-08-31

Family

ID=39827108

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09707983T PL2240179T3 (pl) 2008-02-05 2009-01-23 Imidazopirydazyny jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako leku

Country Status (15)

Country Link
US (1) US8598177B2 (pl)
EP (1) EP2240179B1 (pl)
JP (1) JP5570434B2 (pl)
KR (1) KR20100121612A (pl)
CN (1) CN101980710B (pl)
AU (1) AU2009211890B2 (pl)
BR (1) BRPI0907700A2 (pl)
CA (1) CA2713554C (pl)
ES (1) ES2603302T3 (pl)
HK (1) HK1148956A1 (pl)
IL (1) IL207200A0 (pl)
MX (1) MX2010007892A (pl)
MY (1) MY152685A (pl)
PL (1) PL2240179T3 (pl)
WO (1) WO2009097973A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2602444C (en) * 2005-03-23 2013-03-19 F.Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pyrimidine derivatives as mglur2 antagonists
PL2240486T3 (pl) * 2008-02-05 2016-02-29 Sanofi Sa Sole triazoliowe jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako lek
CA2713550C (en) 2008-02-05 2016-06-14 Sanofi-Aventis Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
US8673890B2 (en) 2009-10-29 2014-03-18 Janssen Pharmaceutica Nv 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist
CA2871599A1 (en) * 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2385039B1 (en) * 2001-04-19 2014-03-12 Eisai R&D Management Co., Ltd. 2-Iminoisoindolinone derivatives as thrombin receptor antagonists
EP1813282A4 (en) * 2004-11-09 2011-03-02 Eisai R&D Man Co Ltd MEANS FOR THE TREATMENT OF ANGIOSPASM IN SUBARACHO-OAL BLOODING WITH THROMBIN RECEPTOR ANTAGONIST AS AN ACTIVE AGENT
DK1966214T3 (en) * 2005-12-21 2017-02-13 Janssen Pharmaceutica Nv TRIAZOLPYRIDAZINES AS TYROSINKINASA MODULATORS

Also Published As

Publication number Publication date
JP5570434B2 (ja) 2014-08-13
IL207200A0 (en) 2010-12-30
WO2009097973A3 (de) 2009-10-01
JP2011511019A (ja) 2011-04-07
CN101980710A (zh) 2011-02-23
US8598177B2 (en) 2013-12-03
CN101980710B (zh) 2013-07-31
EP2240179A2 (de) 2010-10-20
CA2713554C (en) 2016-09-06
HK1148956A1 (en) 2011-09-23
WO2009097973A2 (de) 2009-08-13
CA2713554A1 (en) 2009-08-13
MY152685A (en) 2014-10-31
ES2603302T3 (es) 2017-02-24
KR20100121612A (ko) 2010-11-18
US20110034456A1 (en) 2011-02-10
EP2240179B1 (de) 2016-08-17
MX2010007892A (es) 2010-08-09
AU2009211890B2 (en) 2014-03-13
BRPI0907700A2 (pt) 2015-07-21
AU2009211890A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
IL271132A (en) New preparation and dosage
IL242999B (en) Pyrazolopyrimidine compounds, pharmaceutical preparations containing them and their uses
PL2307391T3 (pl) Tiadiazolilooksyfenyloamidyny i ich zastosowanie jako środki grzybobójcze
ZA201208453B (en) Microbial process and composition for agricultural use
IL206288A0 (en) Novel dosage and formulation
GB0803018D0 (en) Therapeutic compounds and their use
PL2307390T3 (pl) Tiadiazolilooksyfenyloamidyny i ich zastosowanie jako środki grzybobójcze
GB0818241D0 (en) Compounds and their use
IL208081A0 (en) Amido - thiophene compounds and their use
HK1151791A1 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
ZA201007395B (en) Aryl-quinolyl compounds and their use
PL2344449T3 (pl) Związki arylo-fenylo-sulfonamido-cykloalkilowe i ich zastosowanie
EP2349990B8 (en) Aryl-phenyl-sulfonamide-phenylene compounds and their use
PL2240486T3 (pl) Sole triazoliowe jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako lek
PL2240179T3 (pl) Imidazopirydazyny jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako leku
IL212171A (en) 1-Phenylpyrol compounds, pharmaceuticals containing them and their use
HRP20160578T1 (hr) Supstituirani furankarboksamidi i njihova upotreba
GB0821540D0 (en) Lipopeptide compounds and their use
GB0812913D0 (en) Therapeutic compounds and their use
IL207205A0 (en) Triazolopyridazines as par1 inhibitors, their preparation and use as medicaments
GB0801319D0 (en) Compounds and their use
HK1136303A1 (en) Formulation and use of ergosta-7,22-dien-3-ol -722--3-
GB0802128D0 (en) Therapeutic compounds and their use
AP2011005540A0 (en) Disinfection composition and process.
GB0815134D0 (en) Therapeutic compounds and their use